Psilocybin Therapy for PTSD: Evidence, Legal Access, and Cost (2026)

Psilocybin remains experimental for PTSD — but clinical trials are advancing, two states have active legal programs, and a wave of state legislation is moving faster than most people realize. Here's what the evidence actually shows, where you can legally access treatment today, and what it costs.

Quick Reference: Psilocybin for PTSD in 2026

	Status
FDA approval for PTSD	None — clinical trials only
Legal access today	Oregon and Colorado (adults 21+, no diagnosis required)
Phase 2b/3 trial (COMP360)	IND accepted January 2026 — enrolling
Typical session cost	$475–$3,800 (Oregon); $1,500–$3,500 (Colorado)
Insurance coverage	Not covered — Enthea employer benefit only exception
HSA/FSA eligible	Yes
Veteran-specific programs	Yes — Heroic Hearts Project, VETS, Experience Onward

Does Psilocybin Work for PTSD? What the Evidence Shows

The honest answer as of 2026: promising but preliminary.

Unlike ketamine — which has decades of clinical use and multiple published RCTs for psychiatric conditions — psilocybin-specific PTSD research is in early stages. No large-scale randomized controlled trial for psilocybin in PTSD has been completed. Most of what we know comes from one small Phase 2 trial, preclinical fear-extinction research, and extrapolation from psilocybin's stronger evidence base in depression and end-of-life anxiety. For the latest on psilocybin FDA approval timelines and clinical pipeline developments, see our dedicated tracker.

The Key Study: COMPASS Pathways Phase 2 PTSD Trial

The most substantive human data comes from COMPASS Pathways' Phase 2 trial (NCT05312151), published in the Journal of Psychopharmacology in September 2025. The trial enrolled 22 adults with PTSD from adult traumatic events across three sites — King's College London, Mount Sinai Hospital (New York), and Sunstone Therapies (Rockville, MD). Each participant received a single 25mg dose of COMP360 synthetic psilocybin alongside psychological support.

Results on secondary efficacy endpoints:

CAPS-5 total severity score reduction: −9.9 points at week 4; −29.5 points at week 12
Sheehan Disability Scale reduction: −11.7 points at week 4; −14.4 points at week 12
No treatment-emergent serious adverse events
Common side effects: headache (50%), nausea (36%), fatigue (27%)

A qualitative sub-study published in eClinicalMedicine/The Lancet (2025) found that participants reported psilocybin enabled indirect engagement with traumatic material — approaching trauma from a psychological distance rather than confronting it head-on, as required in standard therapies like Cognitive Processing Therapy (CPT) or Prolonged Exposure (PE). For patients who have struggled with or dropped out of traditional trauma therapies, this may be clinically meaningful.

Important limitations: This was an open-label trial with no placebo control and only 22 participants. Effect sizes cannot be reliably established. The results are promising enough to justify Phase 2b/3 investigation — which is now underway — but they do not establish efficacy.

What's Coming: COMP202 Phase 2b/3 Trial

On January 7, 2026, the FDA accepted COMPASS Pathways' Investigational New Drug (IND) application for COMP360 for PTSD, enabling initiation of a late-stage trial (COMP202). The trial design is multicenter, randomized, double-blind, and controlled — two administrations of 25mg COMP360 versus a low-dose active comparator, with a primary endpoint of CAPS-5 score change at week 8.

IND acceptance does not imply efficacy. It means the FDA reviewed the Phase 2 safety data and found it sufficient to permit large-scale human testing. Results from COMP202 are likely several years away.

Note: COMP360 holds FDA Breakthrough Therapy Designation for treatment-resistant depression — not for PTSD. No Breakthrough Therapy Designation for psilocybin in PTSD has been granted.

How Psilocybin Differs from Ketamine for PTSD

Both psilocybin and ketamine ultimately converge on BDNF-mediated neuroplasticity — opening what researchers call "critical periods" for learning and emotional processing. But they arrive there through entirely different mechanisms and produce very different treatment experiences.

	Psilocybin	Ketamine
Primary receptor	Serotonin 5-HT2A agonist	NMDA glutamate antagonist
Acute experience	Mystical/introspective, 4–6 hours	Dissociative, detached, 40 min–2 hours
Typical dosing	1–3 total sessions	Repeated maintenance sessions
Benefit duration	Weeks to months from single dose	Days to ~2 weeks per session
FDA approval (PTSD)	None	None (off-label use)
Legal access today	Oregon, Colorado	49 states (off-label)

The major clinical difference: psilocybin appears to offer longer-lasting effects from fewer sessions, while ketamine provides faster relief but typically requires ongoing maintenance dosing. For PTSD specifically, the indirect trauma engagement that participants described in the COMPASS qualitative study — processing traumatic material from a psychological distance — may represent a meaningful therapeutic advantage over direct exposure-based approaches, though this remains to be confirmed in controlled trials.

Where Is Psilocybin Therapy Legal for PTSD Patients Today?

For a comprehensive overview of where psilocybin is legal across every U.S. state, see our full legal guide.

Oregon

Oregon's Measure 109 program has been operational since June 2023. It is not a medical program — any adult 21 or older can access psilocybin services without a diagnosis, prescription, or referral. PTSD patients go through the same process as any other client.

The process: a preparation session with a licensed facilitator, a 4–8 hour administration session at a licensed service center, and an integration session within 72 hours. Screening excludes active psychosis, current suicidal or homicidal ideation, and lithium use within 30 days. SSRIs are not excluded — approximately 80% of Oregon clients are on them.

No residency requirement. About 60% of Oregon's roughly 16,000 clients served to date have traveled from out of state.

As of early 2026, approximately 22–23 service centers are operational across Oregon. Browse licensed Oregon psilocybin service centers →

Colorado

Colorado's Natural Medicine Health Act (Proposition 122) healing centers began accepting clients in April 2025 — The Center Origin in Denver became the first licensed standard healing center. As of February 2026, 34 state-licensed healing centers have been approved.

Like Oregon, Colorado's program requires no PTSD diagnosis. Adults 21+ access psilocybin services after a health screening. Proposition 122 specifically mandates procedures for "affordable, equitable, ethical, and culturally responsible access" for military veterans among other priority populations. Browse Colorado healing centers →

Everywhere Else

Psilocybin remains a Schedule I controlled substance under federal law. Even with promising clinical data, possession and use outside of licensed state programs or enrolled clinical trials is illegal federally and in most states. The Ninth Circuit ruled in February 2025 that the Right to Try Act does not exempt psilocybin from the Controlled Substances Act.

The Legislative Wave: States Moving on Psilocybin for PTSD

State-level momentum for psilocybin — particularly for PTSD and veteran mental health — is accelerating faster than most coverage reflects. The bills driving this movement are coming predominantly from conservative states with high veteran populations, representing one of the few genuinely bipartisan policy areas in 2026.

Iowa HF 978

Iowa's psilocybin bill passed the House 84-6 in 2025 and survived Iowa's second funnel deadline on March 20, 2026, making it eligible for a full Senate floor vote. A Senate committee amendment narrowed the bill to PTSD patients specifically — adults 21+ with a medical recommendation could access psilocybin produced in-state at licensed facilities under registered facilitator supervision. License applications would begin July 1, 2026 if signed into law.

The bill is sponsored by Rep. John Wills (R-Spirit Lake), a 25-year Iowa National Guard veteran, and is backed by Veterans Exploring Treatment Solutions (VETS). Governor Kim Reynolds vetoed a broader psilocybin bill in June 2025; HF 978 is designed to address her concerns with an Iowa-centric regulatory approach.

South Dakota — Signed Into Law

South Dakota Governor Larry Rhoden signed HB 1099 on March 10, 2026. The law is a trigger bill — it automatically reclassifies synthesized psilocybin from Schedule I to Schedule IV upon FDA approval and DEA rescheduling, instantly legalizing it as a prescription medication for therapeutic settings. Recreational use remains illegal. COMPASS Pathways testified in support; VETS emphasized that more than 125,000 veterans have died by suicide since 2001.

The practical limitation: South Dakota's law does nothing until federal approval occurs. Similar trigger laws have been adopted in North Dakota, Nebraska, and Arizona.

Missouri

Missouri has multiple active psilocybin bills in 2026. HB 1717 would allow military veterans 21+ diagnosed with PTSD, major depression, substance use disorders, or end-of-life needs to access psilocybin while enrolled in a state-funded study, with $2 million in research grants. HB 1643 extends similar access to any adult 21+ with qualifying conditions. The House Emerging Issues Committee passed a combined proposal in February 2026 merging both psilocybin bills with ibogaine legislation.

Other Active State Legislation

Texas enacted SB 2308 in June 2025 — a $50 million ibogaine clinical trial consortium for opioid use disorder, PTSD, and neurological conditions, the largest state-funded psychedelic research initiative in U.S. history. New Jersey signed a $6 million pilot for hospital-based psilocybin research in January 2026. Virginia, New Hampshire, and Oklahoma all have active bills advancing in 2026 sessions.

At the federal level, the VA expanded psychedelic therapy trials to nine VA facilities in November 2025 — the first VA-funded psychedelic research since the 1960s. A companion Senate bill introduced in March 2026 would provide $30 million annually for VA psychedelic centers of excellence, endorsed by the American Legion, DAV, VFW, and Wounded Warrior Project.

What Does Psilocybin Therapy Cost for PTSD?

No traditional insurance covers psilocybin therapy. Psilocybin remains Schedule I federally, and no FDA-approved psilocybin product exists. The one exception is Enthea, a third-party administrator offering psychedelic-assisted therapy as an employer-sponsored benefit — covering psilocybin in Oregon and Colorado for employees at participating companies. HSA, FSA, and HRA funds can be used to pay for sessions.

Oregon Pricing (as of March 2026)

Center	Location	Individual Session	Group Session
Space Psychedelic Clinic	Portland	$900	$475/person
Satya Therapeutics	Ashland	From $1,050	$750/person
Vital Reset	Hood River	$2,000–$3,400	Sliding scale
InnerTrek	Portland	From $1,200	~$850/person
Bendable Therapy	Bend	$3,800	$2,200/person
Bend Inner Alchemy	Bend	$3,200	$5,000 (couples)

Prices subject to change — verify current rates directly with each service center.

Pricing includes preparation, administration (4–8 hours), and integration sessions. Psilocybin product costs approximately $25–$50 for up to 50mg and is typically included or passed through at cost.

Colorado Pricing (as of March 2026)

Colorado's program launched in April 2025. Early pricing data from Boulder healing centers: Happy Rebel Healing (~$2,800/session), Chariot ($1,500–$3,000), Psychedelic Growth ($3,400). My Denver Therapy lists $3,500–$4,500 for individual sessions.

Prices subject to change — verify current rates directly with each healing center.

Financial Assistance Options

The Sheri Eckert Foundation's Psilocybin Access Fund provides sliding-scale financial assistance for Oregon clients who cannot afford treatment. The Heroic Hearts Project offers free or heavily subsidized retreat programs specifically for veterans, with domestic retreats in Bend and Portland. VETS (Veterans Exploring Treatment Solutions) provides grants covering education, integration coaching, and funding for psychedelic-assisted therapies for veterans.

Veteran-Specific Programs

Experience Onward — Portland, OR and Colorado

Founded by Daniel Carcillo, a former NHL player who credits psilocybin with reversing early-onset dementia following seven concussions, Experience Onward offers specialized retreat cohorts for first responders and veterans. Programs include individual full-dose sessions, 3-day retreats with private accommodations, and 6- and 12-week wellness programs. Partnered with Enthea for insurance-reimbursable access.

Heroic Hearts Project

Founded by Jesse Gould, a former Army Ranger diagnosed with PTSD and TBI, Heroic Hearts Project has supported more than 1,000 veterans and veteran spouses. Domestic retreat programs operate in Bend and Portland, Oregon, using licensed Oregon psilocybin service centers. Programs are free or heavily subsidized for veterans through retreat scholarships. heroicheartsproject.org

VA Research Expansion

The VA expanded psychedelic therapy trials to nine facilities in November 2025, including Portland, Oregon; Palo Alto; San Francisco; and Los Angeles — the first VA-funded psychedelic research since the 1960s. A separate VA Palo Alto pilot study (NCT05554094) in 15 U.S. military veterans found that 60% met clinical response criteria and 53% achieved remission at the three-week primary endpoint, with effects persisting in approximately 47% at 12 weeks.

How to Access Psilocybin Therapy for PTSD Today

If you're in Oregon or Colorado: No diagnosis or referral required. Find a licensed service center, complete a screening call, and schedule your preparation session. Browse licensed Oregon psilocybin service centers → or Colorado healing centers →

If you're elsewhere in the U.S.: Legal options are limited to enrolled clinical trials. Search ClinicalTrials.gov for "psilocybin PTSD" for actively recruiting studies. Key trials: COMPASS COMP202 (Phase 2b/3, initiating 2026), University of Washington PsiloStudy (psilocybin for co-occurring alcohol use disorder and PTSD), and the Toronto pilot combining psilocybin with massed Cognitive Processing Therapy.

If you're a veteran: Contact Heroic Hearts Project (heroicheartsproject.org) or VETS (vetsolutions.org) before paying out of pocket — both organizations provide financial assistance and program navigation for veterans seeking psychedelic-assisted therapy.

The Bottom Line

Psilocybin is not an approved treatment for PTSD. The clinical evidence is promising — a Phase 2 trial showed meaningful CAPS-5 reductions at 12 weeks, and a large Phase 2b/3 trial is now underway — but it is preliminary. Anyone considering psilocybin for PTSD should do so with realistic expectations and ideally in consultation with a mental health provider familiar with their history.

What exists today: two legal state programs that PTSD patients can access without a diagnosis, a veteran support infrastructure that has grown substantially in 2025–2026, and a legislative wave moving faster than most national coverage reflects.

For patients who have exhausted standard PTSD treatments — EMDR, CPT, prolonged exposure, medication — and are looking at what's next, Oregon and Colorado represent a legal, regulated pathway that didn't exist three years ago.

Browse licensed psilocybin service centers in Oregon → Browse Colorado healing centers →

Psilocybin remains a Schedule I controlled substance under federal law. This article is for informational purposes only and does not constitute medical advice. Psilocybin services are legal only in Oregon and Colorado for adults 21+. All clinical data cited is drawn from published peer-reviewed research as referenced. Consult a qualified mental health provider before making any treatment decisions.

Frequently Asked Questions

Can psilocybin treat PTSD?

Psilocybin is not an approved treatment for PTSD, but early clinical evidence is promising. A Phase 2 trial by COMPASS Pathways showed a 29.5-point reduction in CAPS-5 PTSD severity scores at 12 weeks after a single 25mg dose. A larger Phase 2b/3 randomized controlled trial (COMP202) received FDA IND acceptance in January 2026 and is now enrolling. Psilocybin holds no FDA Breakthrough Therapy Designation for PTSD. For the latest on psilocybin FDA approval status, see our tracker.

Is psilocybin legal for PTSD treatment?

Psilocybin is legal for adult use (21+) at licensed service centers in Oregon and Colorado — no PTSD diagnosis is required. Everywhere else in the U.S., psilocybin remains a Schedule I controlled substance under federal law. Legal access outside these two states is limited to enrolled clinical trials. For a full state-by-state breakdown of where psilocybin is legal, see our legal guide.

How much does psilocybin therapy cost for PTSD?

In Oregon, psilocybin therapy sessions range from $475 (group) to $3,800 (individual) depending on the service center. In Colorado, early pricing ranges from $1,500 to $3,500 per session. No insurance covers psilocybin therapy. HSA, FSA, and HRA funds can be used. Enthea offers employer-sponsored coverage at select centers.

Can veterans access psilocybin therapy?

Yes. Veterans can access legal psilocybin therapy in Oregon and Colorado without a diagnosis. Veteran-specific programs include the Heroic Hearts Project (free or subsidized retreats), VETS (grants for psychedelic-assisted therapy), and Experience Onward (specialized veteran cohorts). The VA expanded psychedelic therapy trials to nine facilities in November 2025.

Sources

COMPASS Pathways Phase 2 PTSD study. Journal of Psychopharmacology, September 2025. https://journals.sagepub.com/doi/10.1177/02698811251362390
COMPASS qualitative sub-study. eClinicalMedicine/The Lancet, 2025. https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(25)00626-1/fulltext
COMP360 PTSD IND acceptance. COMPASS Pathways press release, January 7, 2026. https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-FDA-Acceptance-of-IND-Application-for-PTSD-and-Hosts-Webinar-on-PTSD-and-TRD/default.aspx
VA Palo Alto veteran psilocybin pilot (NCT05554094). Journal of Affective Disorders, 2025–2026. https://www.sciencedirect.com/science/article/abs/pii/S0165032725010973
VA psychedelic trial expansion to 9 facilities. Military.com, November 2025. https://www.military.com/feature/2025/11/03/va-expands-psychedelic-therapy-trials-ptsd-treatment.html
Iowa HF 978 Senate subcommittee approval. Iowa Capital Dispatch, March 18–19, 2026. https://iowacapitaldispatch.com/2026/03/18/bill-to-establish-state-psilocybin-program-approved-by-senate-subcommittee/
South Dakota HB 1099 signed into law. South Dakota Searchlight, March 10, 2026. https://southdakotasearchlight.com/2026/03/10/psychedelic-mental-health-treatments-will-be-legal-in-south-dakota-if-approved-by-feds/
Oregon psilocybin services data. Psychedelic Alpha tracker. https://psychedelicalpha.com/data/the-oregon-psilocybin-services-tracker
Bendable Therapy Enthea insurance. Willamette Week, April 2025. https://www.wweek.com/news/business/2025/04/19/bend-psilocybin-center-becomes-first-in-oregon-to-offer-insurance-coverage/
DEA 2026 psilocybin production quota. Marijuana Moment. https://www.marijuanamoment.net/dea-boosts-legal-production-levels-for-psychedelics-like-psilocybin-and-dmt-in-final-rule-for-2026/
Colorado healing centers launch. CPR News, February 2026. https://www.cpr.org/2026/02/04/tour-of-three-colorado-psychedelic-healing-centers/
Texas SB 2308 ibogaine research. KUT, June 2025. https://www.kut.org/politics/2025-06-12/texas-will-invest-50-million-into-psychedelic-research-under-new-law
South Dakota HB 1099 Senate committee hearing (VETS veteran suicide testimony). South Dakota Searchlight, February 25, 2026. https://southdakotasearchlight.com/2026/02/25/bill-supporting-therapeutic-use-of-psychedelic-compounds-clears-senate
Colorado Proposition 122 (Natural Medicine Health Act) overview. Vicente LLP. https://vicentellp.com/insights/natural-medicine-health-act-psychedelic-medicine-colorado/
Experience Onward profile. Healing Maps. https://healingmaps.com/welcome-to-experience-onward-a-legal-state-licensed-mushroom-service-center-in-portland-oregon/
Heroic Hearts Project (Jesse Gould founder bio). https://heroicheartsproject.org
Colorado psilocybin therapy Boulder healing centers pricing. Axios Boulder, December 2025. https://www.axios.com/local/boulder/2025/12/01/colorado-psilocybin-therapy-boulder-healing-centers